[Legal Perspective] Can Human Genes Be Patented?

by JD Supra Perspectives


Earlier this month, the United States Supreme Court heard oral arguments in a case that comes down to a single question: can human genes be patented? There's a lot riding in the outcome of Association for Molecular Pathology v. Myriad Genetics, Inc. explains attorney Randy Clower of law firm Phillips Lytle:

“… if the Court determines that isolated DNA molecules are tantamount to genetic products of nature, many, if not all, claims in the more than 30,000 issued patents directed to such subject matter will be at risk.”

The high court justices are expected to rule in June. In the meantime, here's a legal perspective on the case from lawyers on JD Supra:

There’s no clear definition of “human gene”

Antoinette Konski of Foley & Lardner: “’Are human genes patentable’ is the sole question before the Supreme Court. Hidden within this deceptively simple question is what is specifically meant by the phrase ‘a human gene.’ During this dispute, the patent claims at issue have been argued to cover a complete human gene (including contiguous coding and non-coding regions), artificial, human-generated, contiguous DNA sequences (cDNA and recombinant DNA) and functional gene fragments being identical to portions of a human gene… The ultimate construction of the term ‘a human gene’ is key to whether or not gene patents preempt the use of laws and products of nature; a policy issue that has been heavily briefed and argued by the parties and amici.”

Patent law on the issue is vague (and complicated)

Randy Clower again: “The sole question before the Court concerns whether human genes qualify as patentable subject matter pursuant to [Section 101 of the Patent Act], which recites that ‘any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof …’ is eligible for patent protection. Patent eligible subject matter, moreover, has been apophatically defined by the Supreme Court in previous decades… These ‘exceptions’ to patent eligibility, i.e., abstract ideas, laws of nature, and natural phenomena (also referred to as the ‘products of nature’ exception), are coterminous with the statutory categories outlined above, but serve as ‘carve-outs’ which proscribe patent eligibility.”

The question before the court is misleading

Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff: “The Supreme Court's grant of certiorari over the question ‘Are human genes patentable’ had raised for many the specter of an uninformed generalist court rendering a decision containing dicta that would negatively affect biotechnology.  This possibility is real, in view of the voices raised against patenting human genes based on moral, policy, or ideological grounds.  While strongly felt, these sentiments are based, in large part, on a misunderstanding or mischaracterization of either the facts or the law, specifically patent law. These misstatements include arguments based on patent claims somehow exerting an ownership interest in individual's DNA, or that isolated human nucleic acid claims preempt future research (in the face of thousands of published scientific journal articles published since the BRCA gene patents were granted), or that isolated DNA patents inhibit future technologies like personalized medicine.

The parties involved disagree on certain essential terms

Antoinette Konski of Foley & Lardner: “[T]he ACLU argues that the term ‘a human gene’ includes isolated human DNA, cDNA and fragments, but excludes recombinant DNA… The ACLU argues that in contrast to recombinant DNA [(DNA that results from choosing fragments from genes or chromosomes that do not appear together in nature and ‘stitching them together’)], DNA isolated or purified from a human (complete gene sequences and fragments of genes) should not be patent-eligible because the acts of finding, separating and characterizing a DNA molecule do not present structural distinctions between the DNA or gene as it exists in the human body.”

And then Ms. Konski again: "Myriad noted in its brief, […] [that its] patent claims are not an attempt to patent ‘human genes’ but rather isolated DNA molecules not found in nature… Myriad also responded to the ACLU’s contention that standard isolation results in random DNA fragments that are identical to those that exist in the body. By definition, Myriad noted, isolated DNA is a molecule that has been removed from the body. It cannot simultaneously be removed from the body and be in the human body. With respect to the ACLU’s claim that covalent bonds of DNA molecules may be broken in the body, this fact, Myriad argued, is irrelevant because this assertion omits critical elements of the definition of isolated DNA. Isolated DNA is more than just DNA with bonds broken, Myriad explained, the DNA must also be separated from the body and other DNA not of interest."

The patents in question will soon be irrelevant

Kevin Noonan again: "… the day of the DNA patent claim is rapidly coming to a close.  These types of patents were first filed directed to specific genes encoding biologically relevant proteins having therapeutic benefits…Myriad's BRCA gene patent claims are in this form, one of the reasons why these claims are not infringed by genetic diagnostic methods used today. The vast majority of gene patent applications, however, were filled as the result of the Human Genome Project. […] [B]ecause almost all of these patents were filed at the turn of the century, and the term of these patents will expire no later than 20 years after application filing, the ‘problem’ of gene patents will disappear no later than 2020 (and in many instances much earlier…)."


Stay tuned for the Supreme Court's decision on this well-watched case.


Written by:

JD Supra Perspectives

JD Supra Perspectives on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.